This study evaluated the detection of tumors using in vivo imaging with a commercially available and systemically administered protease-activatable fluorescent probe, ProSense. To this end, we analyzed the delivery and uptake of ProSense as well as the target protease and its cellular source in a mouse xenograft tumor model. In vivo and ex vivo multiwavelength imaging revealed that ProSense signals accumulated within tumors, with preferential distribution in the vascular leakage area that correlates with vasculature development at the tumor periphery. Immunohistochemically, cathepsin B, which is targeted by ProSense, was specifically localized in macrophages. The codistribution of tenascin C immunoreactivity and gelatinase activity provided evidence of tissue-remodeling at the tumor periphery. Furthermore, in situ zymography revealed extracellular ProSense cleavage in such areas. Colocalization of cathepsin B expression and ProSense signals showing reduction by addition of cathepsin B inhibitor was confirmed in cultured macrophage-derived RAW264.7 cells. These results suggest that increased tissue-remodeling activity involving infiltration of macrophages is a mechanism that may be responsible for the tumor accumulation of ProSense signals in our xenograft model. We further confirmed ProSense signals at the tumor margin showing cathepsin B + macrophage infiltration in a rat colon carcinogenesis model. Together, these data demonstrate that systemically administered protease-activatable probes can effectively detect cancer invasive fronts, where tissue-remodeling activity is high to facilitate neoplastic cell invasion.
Introduction
Molecular imaging using exogenous tumor-specific fluorescent probes is becoming an essential tool for the study of diseases, therapeutic effects, and clinical applicability [1] [2] [3] . Human clinical studies for diagnostic and image-guided surgery are also emerging [4, 5] . Tumor imaging with fluorescent probes has the potential to promote a paradigm shift in surgical inspection by enabling the localization of lesions that are difficult or impossible to detect by visual observation or palpation. This improved tumor detection can then improve patient outcomes by identifying much smaller lesions and/or excising tumor tissue more completely. However, the factors affecting tumor imaging performance, such as target molecule activity, tumor growth environment, vasculature, and stromal components, can vary on the basis of the fluorescent probe design and type of cancer. Therefore, to assess their clinical applicability, it is important to understand how the biologic characteristics of these tumors affect the in vivo imaging of these fluorescent probes.
Proteases have pivotal roles in altering local microenvironments during embryonic development and growth as well as in both physiological and pathologic tissue-remodeling processes. Cysteine cathepsins, simply referred to as cathepsins in this study, consist of 11 family members in humans (B, C, H, F, K, L, O, S, L2/V, W, and X/Z). Cathepsins collectively have important roles in lysosomal protein degradation and individually contribute to pathologic conditions [6] . Specifically, cathepsin B is one of the most prominent proteases in the tumor proteolytic network and is upregulated in many different tumor microenvironments, from early neoplastic to advanced metastatic lesions [7, 8] . Cathepsin B is frequently translocated from lysosomes to the cell surface and/or secreted into the extracellular matrix of tumor cells to help their invasive growth by local activation of tissue proteolysis [9, 10] . The central role of cathepsin B in carcinogenesis suggests that it is not only a promising target for chemotherapy and chemoprevention but also for tumor detection.
Previous reports have shown that in vivo fluorescent imaging of cathepsin B activity is capable of detecting tumors with high sensitivity [11] . The cathepsin probe is an activatable graft copolymer coupled with quenched fluorophores that are released after cathepsin B cleavage, which allows for the detection of small or early lesions. The probe is also designed for prolonged circulation by attaching several polyethylene-glycol side chains to the polymer. A commercially available probe, ProSense, is preferentially hydrolyzed by cathepsin B but can also be activated through proteolysis by other cathepsins, such as cathepsin L and cathepsin S. ProSense has been shown to detect a variety of experimentally induced tumors of the colon, ovary, mammary gland, pancreas, and esophagus [12] [13] [14] [15] [16] . However, the mechanisms underlying the tumor specificity of ProSense signals are still unclear because this probe is exposed to numerous complex in vivo processes. Systemically administered ProSense is delivered to tumor tissue during prolonged circulation, cleaved by target cathepsins in the local tumor microenvironment, and is then retained within the tumor tissue. Therefore, each of these processes needs to be investigated, as well as the relationship between them within the same tumor, to clearly understand the tumor specificity of ProSense.
In this study, we aimed to clarify how the biological characteristics of tumors affect the in vivo imaging of systemically administered proteaseactivatable fluorescent probes. For this purpose, we performed a timecourse analysis of delivery and uptake of ProSense in a mouse xenograft model at both the macroscopic and microscopic levels using in vivo and ex vivo multiwavelength imaging techniques. We then determined the target molecules and cellular sources that generate the ProSensecleaving activity within the tumor. We further confirmed the specificity of ProSense signals with protease expression in cultured cells. To investigate the influence of inflammation and immunity as well as carcinogenesis on the tumor microenvironment, we analyzed ProSense signals in an immunocompetent rat colon carcinogenesis model induced by azoxymethane (AOM).
Materials and Methods

Cancer Cell Lines
Human colon tumor cell lines HT29 and HCT116 and a murine macrophage-derived cell line RAW264.7 were purchased from DS Pharma Biomedical (Osaka, Japan). HT29 or HCT116 cells were cultured in McCoy's 5A medium (Life Technologies, Carlsbad, CA) supplemented with 10% FBS, 100 U/ml penicillin, and 0.1 mg/ml streptomycin. RAW264.7 cells were cultured in Dulbecco's modified Eagle's (DME) medium (Life Technologies) supplemented with 10% FBS, 100 U/ml penicillin, and 0.1 mg/ml streptomycin. Cells were routinely passaged at subconfluence. Only low-passage cells (passage < 10 times) were used.
Animal Model
To develop a xenograft tumor model, a total of 12 male BALB/c nu/nu mice (4 weeks old) were purchased from Japan SLC Inc (Hamamatsu, Japan). They received CA-1 (CLEA Japan Inc, Tokyo, Japan) as a basal diet and tap water ad libitum period. At 5 to 6 weeks of age, the mice were inoculated subcutaneously with 5 × 10 6 HT29 or HCT116 cells in 0.1 ml of medium.
To develop an immunocompetent colon carcinogenesis model, 11 male F344 rats (4 weeks old) were purchased from Japan SLC Inc. The rats received CE-2 (CLEA Japan Inc) as a basal diet and water ad libitum throughout the experimental period. Starting at 6 weeks of age, rats were given subcutaneous injections of AOM (Sigma-Aldrich, St Louis, MO; 15 mg/kg body weight) once a week for 3 weeks as described previously [17] .
All animal experiments were performed in accordance with the guidelines for animal experimentation of the Facility of Agriculture, Tokyo University of Agriculture and Technology.
In Vivo and Ex Vivo Imaging
To detect cathepsin activity, we used ProSense 750/750 EX (PerkinElmer, Waltham, MA). To visualize the architecture of the blood vessels, we used fluorescein-conjugated Lycopersicon esculentum lectin (fluorescein-tomato lectin; Vector Laboratories Inc, Burlingame, CA) or DyLight 594-conjugated Lycopersicon esculentum lectin (DyLight 594-tomato lectin; Vector Laboratories Inc) [18] . We used a blood pool imaging agent, AngioSense 680/680 EX (PerkinElmer), to detect nonspecific probe delivery and uptake [19] .
To image whole animals noninvasively, we used an epifluorescence imaging system (OV100; Olympus, Tokyo, Japan). We used a multiwavelength laser scanning microscope (IV100; Olympus) to acquire high-magnification and high-resolution images.
In the mouse xenograft tumor model, in vivo imaging was performed 1 to 3 weeks after inoculation of tumor cells. To reduce autofluorescence derived from the animals' intestinal contents, mice received an alfalfa-free CA-1 diet (CLEA Japan Inc) 2 to 3 days before in vivo imaging [20] . A solution mixture of 2 nmol each of ProSense 750 and AngioSense 680 in a total volume of 165 μl was injected intravenously into tumor-bearing mice. To capture the distribution kinetics of these reagents, fluorescent images were taken 10 minutes and 24 to 30 hours after injection. Fluorescein-tomato lectin (200 μg/100 μl) was injected intravenously and allowed to circulate for 5 minutes, followed by imaging. Mice were euthanized immediately after in vivo imaging, and tumors were excised and cut in half longitudinally. Ex vivo imaging of the tumor cut surface was performed to analyze the distribution of reagents within the tumor tissue. After ex vivo imaging, tissues were fixed in phosphate-buffered 10% formalin (pH 7.4) for at least 24 hours. The other half of the tissue sample was snap frozen in liquid nitrogen. To measure the probe fluorescent intensity, whole-animal and high-resolution images were first obtained by the OV100 and IV100 microscopes, respectively, and then analyzed using their respective software.
In the rat colon carcinogenesis model, a solution mixture of 10 nmol of ProSense 750/750 EX and 5 nmol of AngioSense 680/680 EX in a total volume of 450 μl was injected intravenously 23 to 27 hours before Translational Oncology Vol. 6, No. 6, 2013 In Vivo Imaging of Protease-Activatable Probe Onda et al.
euthanasia at 28 to 37 weeks post-initiation. DyLight 594-tomato lectin (250 μg/250 μl) was injected intravenously and allowed to circulate for 20 minutes before euthanasia. Tumors were excised and processed for histologic analysis or immunofluorescence. Ex vivo imaging of the tumor cut surface was performed as described above.
Histology, Immunohistochemistry, and Immunofluorescence
To identify ProSense + -tissue component(s) within the tumor tissue, unfixed cryosections from ProSense 750-injected tissue sample were scanned with IV100, fixed with 4% paraformaldehyde, and then immediately stained with hematoxylin and eosin (H&E) for microscopic observation. AOM-induced rat colon tumors were diagnosed according to previously published criteria [21] .
Immunohistochemistry (IHC) was performed in paraffin-embedded tissue sections by incubation with primary antibodies referred to in Table W1 . Immunodetection was carried out with an HRP-avidin-biotin complex using a VECTASTAIN Elite ABC kit (Vector Laboratories Inc), with DAB/H 2 O 2 as the chromogen. Sections were counterstained with hematoxylin.
Immunofluorescence was performed using methanol-fixed cryosections for mouse tissues or paraffin-embedded tissue sections for rat tissues and the antibodies referred to in Table W1 . The sections were incubated with primary antibodies and then with speciesappropriate Alexa Fluor-conjugated antibodies (1:200; Life Technologies) and counterstained with 4′,6-diamidino-2-phenylindole, dilactate (DAPI; Life Technologies).
Microscopic observation was performed with a fluorescent virtual microscopy system (VS120 Fluorescence; Olympus) or a fluorescent microscope (BX53; Olympus). Fluorescent images were analyzed using IV100 software. ) were added into the chamber and allowed to adhere and grow in culture medium containing 10% FBS/DME's medium for 1 day. ProSense signals were detected as described above, followed by immunofluorescence of cathepsin B with CD45. For protease inhibition assay, RAW264.7 cells were cultured in the presence of cell-permeable pan-cathepsin inhibitor (E64d; Sigma-Aldrich) or cell-permeable cathepsin B inhibitor (CA074Me; EMD Millipore, Billerica, MA). RAW264.7 cells (4 × 10 4 ) were seeded into a noncoated chamber slide. After 2 days, the medium was replaced with HBSS containing vehicle (DMSO), E64d (5, 25, or 50 nM), or CA074Me (5, 25, or 50 nM). After incubating at 37°C for 1 hour, 5 nM of ProSense in the presence or absence of inhibitor was added, and the cells were incubated at 37°C for 3 hours. ProSense signals were detected as described above. All experiments were performed in duplicate.
Cultured Cell Experiments
In Situ Zymography
In situ zymography was performed on the fresh-frozen sections according to the method described previously [22] , with some modifications. Gelatinase activity or ProSense-cleaving activity was detected in an unfixed cryosection using fluorescein-quenched gelatin (DQ gelatin; Life Technologies) or ProSense 680, respectively. Cryosections were overlaid with a solution of 50 mg/ml DQ gelatin or 13 nmol/ml ProSense 680, mixed with 1% (wt/vol) low-melting temperature agarose in phosphate-buffered saline (PBS; pH 7.4) containing propidium iodide (BD Biosciences, San Jose, CA) or DAPI to counterstain nuclei. Fluorescent images were acquired using either the IV100 or BX53 microscope.
Statistical Analysis
Fluorescent intensity data from the whole-animal images between the two groups were compared using a Student's t test when the variance was proven to be homogeneous among the groups by the equal variance test. When a significant difference in variance was observed, Aspin-Welch t test was performed. P values <.05 were considered significant.
Results
ProSense Signals in Xenograft Tumor Model
Although histopathologic patterns of xenograft tumors were different between HT29 and HCT116 in terms of the production of stromal connective tissue ( Figure W1 The whole-tumor view at the cut surface showed that ProSense signals were primarily in stromal tissue at the tumor periphery and between the tumor parenchyma but rarely within the tumor parenchyma ( Figure 1C ). At high magnification (×20), strong ProSense signals were observed in the stromal area in both of the two xenograft tumors ( Figure 1D and data not shown).
In Vivo Delivery and Uptake of ProSense within Tumor Xenografts
In vivo imaging revealed that AngioSense signals increased slowly within tumor portions after injection of the probes, reflecting vascular leakage of AngioSense specific to tumors (Figure 2A ). Similar to AngioSense, ProSense also slowly increased within tumors, although the kidney showed a rapid increase in ProSense signals within 10 minutes after injection, reflecting renal clearance of uncleaved ProSense probes. Ear tissue rarely showed any increase in either AngioSense or ProSense signals ( Figure 2B ).
With ex vivo tumor imaging, we observed that ProSense signals were localized within cell cytoplasm, whereas AngioSense signals were broadly distributed in interstitial tissue ( Figure 2C ). Wholetumor images at the cut surface showed tomato lectin signals in conjunction with the vasculature at the tumor periphery, but the tumor center showed reduced signals. This reflects the low density of the vasculature in the center compared with the tumor periphery ( Figure 2D) . Similarly, AngioSense signals were also primarily observed at the tumor periphery. Merged images of tomato lectin signals, AngioSense signals, and ProSense signals demonstrated that ProSense signals were distributed in areas showing high vascular density. At high magnification (×20), ProSense + cells were preferentially observed in areas with increased vascular leakage at the tumor periphery, in contrast to the weak signals observed in areas with low vascular leakage at the tumor center ( Figure 2E ). Intensity profile analysis for tomato lectin or AngioSense with ProSense corroborated the imaging results of these signal distributions ( Figure 2F ).
Immunoreactivity for Cathepsins and Their Cellular Identity in Tumor Xenografts
Immunolocalization of cathepsin B, cathepsin L, and cathepsin S was similarly observed in the stroma at the tumor periphery ( Figure 3 , A-C ). Cathepsin B localized strongly in the cytoplasm of stromal cells and faintly in the cytoplasm of tumor cells. These stromal cathepsin B + cells were prominently observed at the tumor periphery. Although fewer stromal cells were distributed between tumor lobules than in the tumor periphery, those distributed between tumor lobules also showed strong cathepsin B immunoreactivity. With regard to cathepsin L, immunoreactive cells also showed weak cytoplasmic expression in the stroma at the tumor periphery, rarely in the tumor parenchyma, and no expression in tumor cells. Cathepsin S localized in the cytoplasm of stromal cells at the tumor periphery and at the interlobular connective tissue and also diffusely but weakly in the cytoplasm of tumor cells. The distribution of ProSense signals was found to be more closely related to that of cathepsin B than that of other cathepsins ( Figures 2D  and 3 , A-C). ProSense signals were largely colocalized with cathepsin B fluorescence in the stromal areas at the tumor periphery ( Figure 3D ). Colocalization of ProSense signals and cathepsin B was also confirmed in Kupffer cells in mouse livers ( Figure W3 ).
In conjunction with cathepsin B immunoreactivity, CD68 + cells distributed mostly at the tumor periphery ( Figure 4A ). There was a good correlation between CD68 with cathepsin B in a scattergram. However, scattergrams of α-smooth muscle actin (SMA) + or CD31 + cells with cathepsin B showed a "two-tailed" split [23] , reflecting a dissociation of their distribution with cathepsin B (Figure 4 , A-C ). Imaging of double-stained cathepsin B and CD68 tissue under high magnification (×20) also revealed identical cellular distribution of these immunoreactivities. Furthermore, immunofluorescence of cathepsin B with other leukocyte markers, CD45, CD11b, Gr-1, or F4/80, in serial sections revealed that cathepsin B-expressing cells mostly coexpress all of these markers similarly with CD68 ( Figure W4 ). Again, CD31 and α-SMA did not colocalize with cathepsin B, except for the colocalization of α-SMA with cathepsin B in blood vessel walls (Figure 4 , A-C). Intensity profiling data showed similar distribution patterns between cathepsin B and CD68 or CD31, corresponding to the profile of ProSense signals and vascular probe signals within the tumor tissue ( Figure 2F and Figure 4 , B and C). α-SMA immunoreactivity, however, did not show a similar intensity profile ( Figure 2F and Figure 4 , A and C). Colocalization of ProSense signals was observed with immunofluorescence of cathepsin B or CD68 in identical tissue section imaging ( Figure 4D) .
In vitro studies using cultured cells revealed that RAW264.7, a murine macrophage-derived cell line, showed high ProSense signals and strong cathepsin B immunoreactivity, whereas HT29 or HCT116 cells showed low ProSense signals and weak cathepsin B Tumor Proliferation and Tissue-Remodeling Activity in a Xenograft Tumor Model IHC for proliferating cell nuclear antigen (PCNA) revealed higher proliferative activity of tumor cells at the tumor periphery than at the center ( Figure 6A ). Collagen IV immunoreactivity was rarely observed at the tumor margin, in contrast to the scattered distribution in stromal cells within tumor parenchyma. Unlike collagen IV, tenascin C immunoreactivity was observed at the tumor margin. Gelatinase activity also showed a similar pattern of immunoreactivity as tenascin C by in situ zymography of DQ gelatin ( Figure 6B ). In situ zymography of ProSense revealed that ProSense cleavage was observed at the collagenous tissue components at the tumor periphery ( Figure 6C ).
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ProSense Signals in a Rat Colon Carcinogenesis Model
Ex vivo imaging detected ProSense signals in rat colon tumors induced by AOM ( Figure 7A ). The whole-tumor view at the cut surface showed ProSense signals distributed at the tumor margin showing high vascular density and increased vascular leakage ( Figure 7B ). These ProSense signals were localized within the cell cytoplasm (data not shown). Double staining of cathepsin B and CD68 showed cathepsin B + macrophages had infiltrated the tumor margin, corresponding to ProSense signals within the tumor ( Figure 7 , B and C). α-SMA and CD31, however, did not show colocalization with cathepsin B, except for the colocalization of α-SMA with cathepsin B in blood vessel walls. In some tumors, tumor cells appeared to express cathepsin B, in contrast to the lack of cathepsin B expression in the adjacent normal colon mucosa.
Discussion
In this study, we observed a time-dependent accumulation of AngioSense in xenograft tumors by selective leakage from the microvasculature identified by tomato lectin. This is suggestive of an enhanced permeability and retention (EPR) effect of macromolecules [24] . We also observed a slow accumulation of ProSense signals in the areas showing EPR effects within tumors. These data suggest that ProSense probes are delivered to tumors in this manner. Alternatively, it is possible that ProSense probes could be effectively delivered to, and accumulate in, areas with increased vascular leakage similar to AngioSense probes. Furthermore, we observed this EPR effect in the rat colon carcinogenesis model, which partially recapitulates clinical carcinogenesis. Our results suggest that EPR effect-based imaging agents like ProSense can be applicable in clinical settings for tumor detection.
We also observed that the cytoplasmic localization patterns of ProSense signals showed a similar distribution with cathepsin B + macrophages in tumor xenografts. The accumulation of ProSense signals has also been reported in conjunction with intestinal polyp accumulating macrophages in a genetically engineered mouse model [25] . ProSense + macrophages were also found in mouse xenograft gliomas [26] . In the present study, we also found that cultured cells of RAW264.7, a macrophage-derived cell line, revealed cathepsin B expression and high ProSense signals. These results suggest that ProSense + cells in our tumor xenografts were cathepsin B + macrophages. We further found extracellular ProSense-cleaving activity in areas with accumulating cathepsin B + macrophages. Considering the It has been reported that tumor cells could contribute to the accumulation of ProSense probes [15] . However, the xenograft tumor models used in the present study showed only low ProSense signals, consistent with the faint expression of cathepsin B we observed in colon tumor cells. In the AOM-induced colon tumors, although we could not detect ProSense signals in tumor cells, cathepsin B was expressed in some tumor cells. Together, these data suggest that macrophages are the major source of ProSense signals in tumor tissues, consistent with previous reports [27] . Therefore, ProSense signal intensity is likely determined by the degree of macrophage infiltration. When using these probes to detect tumors, it may be important to address not only the level of cathepsin protease activity but also the endocytic activity of the cells [28] .
ProSense signals and cathepsin B + macrophages in the tumor xenografts were mainly distributed at the tumor periphery, where we observed a higher density of vasculature and PCNA + tumor cells than in the center. Although we also observed the localization of tenascin C and gelatinase activity at the tumor margin, collagen IV did not accumulate in the same way as reported by others [29] . Tenascin C is an extracellular matrix glycoprotein that has a role in tissue-remodeling [30] . In the present study, we further found increased extracellular ProSense cleavage at the tumor periphery. Although tumor xenografts did not show apparent invasive growth into the surrounding tissues, these results suggest that tissue-remodeling occurred at the tumor periphery in response to tumor proliferation. We also found that cathepsin B + macrophages were mainly distributed around blood vessels at the tumor periphery. Macrophages that aggregate around the tumor vasculature function in tissue-remodeling [31, 32] . Therefore, our results suggest that, in addition to the EPR effect, the increase in tissue-remodeling involving cathepsin B + macrophage infiltration is a potential mechanism for the accumulation of ProSense signals within tumors.
We also evaluated how inflammation in the tumor microenvironment may affect ProSense accumulation within tumors using an immunocompetent AOM-induced rat colon carcinogenesis model. This immunocompetent model renders a natural tumor-host interaction. Notably, we could detect ProSense signals in conjunction with increased vascular leakage at the tumor stroma, especially at the tumor margin showing macrophage infiltration. Recent reports using immunocompetent animal models have also detected tumors by enhancing ProSense signals at the tumor margin [14, 33] . In human colorectal cancers, invasive fronts express cathepsin B, showing high activity to facilitate tissue-remodeling [34, 35] . Although macrophage infiltration is positively correlated with a favorable outcome in some human colorectal cancers, macrophages could be protumorigenic or antitumorigenic depending on the degree of cellular contact with neoplastic cells [36] [37] [38] . These data suggest that ProSense can effectively detect cancer invasive fronts where tissue-remodeling activity is high to facilitate neoplastic cell invasion.
In conclusion, the higher ProSense delivery and uptake at the tumor periphery are likely the result of the infiltration of cathepsin B + macrophages in the stroma and the high-density vasculature. We also demonstrated that ProSense signal activation occurs in the extracellular space, and then the activated molecules accumulate in the macrophages. This suggests that ProSense is a clinically valuable tool for the detection of malignant tumors that require tissue-remodeling. Therefore, the clinical introduction of intraoperative protease imaging may have the potential to improve the accuracy of tumor resections. 
